Biomerica Expands into Canada with IBS Diagnostic Platform
Event summary
- Biomerica launched its inFoods® IBS diagnostic platform in Canada through partnerships with Phoenix Airmid Biomedical and CanAlt Health Labs.
- Canada has an 18% IBS prevalence rate, with up to 5 million potential patients.
- Phoenix Airmid will handle distribution, while CanAlt Health Labs will provide certified laboratory processing.
- The platform's clinical validation was published in the journal Gastroenterology in June 2025.
The big picture
Biomerica's entry into Canada marks a strategic expansion into a high-prevalence IBS market, addressing a significant unmet need with its non-pharmaceutical diagnostic-guided therapy. The partnerships with Phoenix Airmid and CanAlt Health Labs provide a robust infrastructure for scaling the platform's reach. This move aligns with broader industry trends toward personalized medicine and diagnostic innovation in gastrointestinal health.
What we're watching
- Market Penetration
- How Biomerica will leverage its partners to achieve significant physician and patient adoption in Canada.
- Regulatory Compliance
- Whether the platform will face any regulatory hurdles in the Canadian market.
- Revenue Growth
- The pace at which Biomerica can scale its revenue from the Canadian launch.